Acute Leukemias - Republican Scientific Medical Library

More documents

Recommendations

Info

290 Subject Index Allo SCT, Allogeneic Stem Cell Transplant 5 allogeneic hematopoietic stem cell transplantation (HSCT 57 Allogeneic Stem Cell Transplant (Allo SCT) 5 allogeneic stem cell transplantation 150 allopurinol 281 AML, see acute myeloid leucemia 1 – Allogeneic Stem Cell Transplant (Allo SCT) 5 – Autologous Stem Cell Transplant (Auto SCT) 6 – CBF 7, 13 – chemotherapy-resistant 5 – chromosome abnormalities 9 – Colony Stimulating Factors (CSFs) 6 – cytogenetic findings 3 – Investigational Therapy 8–9 – – elderly Patients 8 – prognostic heterogeneity 5 – therapy 1–2 – – 3+7 2 – treatment 2 – treatment/therapy 10 – – start 10 – white blood cell index 4 – younger patients 9–10 – – with a normal karyotype 10 AML, see acute myeloid leucemia , treatment 1 amsacrine 61 anemia 77 ankylosing spondylitis 85 antecedent hematologic disorder (AHD) 3 anthracycline 7, 162, 192, 275 anthracyclines 61 anti-B4bR 133 APL, see acute promyelocytic leukemia 22 – gemtuzumab ozogamicin 69 Ara-C 183, 217, 231 ara-C, see cytosine arabinoside 2 arachnoid tissue 265 arsenic trioxide 66–67 asparaginase 61, 101, 140, 204, 211, 217, 231, 242 Aspergillus flavus 282 ataxia telangiectasia mutated gene (ATM gene) 125 ataxia-telangiectasia 83 ATRA, see all trans-retinoic acid 33 Auto SCT, see Autologous Stem Cell Transplant 6 Autologous Blood and Marrow Transplantation Registry (ABMTR) 210 Autologous Stem Cell Transplant (Auto SCT) 6 5-azacytidine 241 B B-ALL/NHL 2002 protocol 173 B-NHL90 protocol 172 background hematopoiesis 24–25 basophilic granules 122 BCR gene 96 BCR-ABL 237, 250, 255 – tyrosine kinase inhibitors 237 BCR-ABL genes 177 BCR-ABL protein 180 BCR/ABL 216 – tyrosine kinase 218 benzene 53 bilineage leukemia 123 bilineal acute leukemia 32 bilirubin 3, 9 biphenotypic leukemia 123 blood-brain barrier (BBB) 266 Bloom syndrome 83 bone marrow (BM) infiltration 203 bone marrow blasts 181 bone marrow sampling 28 bone marrow transplant 276 – human leukocyte antigen- (HLA) matched 276 Bone marrow transplantation (BMT) 270 Burkitt, lymphoma 112 Burkitt blasts 120 Burkitt leukemia 112, 133, 164 Burkitt lymphoma 191 Burkitt lymphoma/leukemia 111 Burkitt lymphome, HIV-positive 199 Burkitt’s leukemia/lymphoma 161 Burkitt’s lymphoma 209 Burkitt-tailored chemotherapy 198 Burkitt-type leukemia/lymphoma 141 busulfan 220, 233 busulfan/cyclophosphamide (Bu/Cy) 14 C c-myc gene 125 C/CAAT enhancer binding protein a (C/ EBPa) 36 calcinosis cutis 283 CALGB 10, 13, 195, 219, 234 CALGB, see Cancer and Leukemia Group B 3 calicheamicin 64 CALLA 115 Campath-1H 221 Cancer and Leukemia Group B (CALGB) 3, 137 carmustine 148 CBF, Core binding factor 8 CBF, see core binding factor 3 CD19 242 2-CDA 212 central nervous system (CNS) 207, 263, 285 – relapse 70 cerebrospinal fluid (CSF) 110, 264 childhood leukemia 88 – maternal use of pharmaceuticals 88 – parental diets 88 chromatin 111 chromosomal aberrations 216 chromosome abnormalities 9 chromosome rearrangements 250 – leukemia-specific 250 chromosome X 100 chronic lymphocytic leukemia 86 chronic lymphocytic leukemia (CLL) 111 chronic myelogenous leukemia 26 chronic myelogenous leukemia (CML) 233 chronic myeloid leukemia 218 chronic myeloid leukemia (CML) 58, 120, 177, 179, 241 cladribine 239, 278 clofarabine 11, 64, 134, 240, 278 cloretazine 11, 65 CML lymphoid blast crisis (CML-LBC) 179 CML, see chronic myelogenous leukemia 233 – philadelphia chromosome positive 233 CML, see chronic myeloid leukemia 179, 241 – lymphoid blast crisis (CML-LBC) 179 CNS, irradiation 211 CNS, see central nervous system 70, 263, 265–266 – cytologic examination 263 – imaging techniques 265 – leukemia 269 – – treatment 269 – prophylaxis 263, 266, 269, 271 – – toxicity 271 – relapse 207, 263, 269 – thrombosis 285 CNS, see, central nervous system, relapse 277 Comparative genomic hybridization (CGH) 192 core binding factor 34 core binding factor (CBF) 3 Core binding factor (CBF) 8 core binding factors (CBFs) 52 core binding factortranslocations 34 corticosteroid 156 cox regression analysis 264 cranial irradiation 270–271 creatinine 3, 9
a Subject Index 291 CREB, see enhancer binding protein 36 CSFs, see Effect of Colony Stimulating Factors 6 CTL, see cytotoxic T-lymphocytes 13 Cushing’s syndrome 265 cyclin-dependent kinase inhibitor (CDKI) 127 cyclophosphamide 132, 137, 140–142, 148, 161, 193, 207, 211, 220, 232–233, 237, 270, 275 cyclophosphamide (CP) 169 cyclosporine 233 cytarabine 132, 146, 148, 237, 239, 267–268, 270, 276 cytarabine (AC) 169 cytarabine (Ara-C) 142 cytidine deaminase 267 cytochemistry 29, 113 cytogenetic abnormalities 52, 83 cytoplasm 111 cytoreductive therapy 225 cytosine arabinoside 35 cytosine arabinoside (ara-C) 2 cytospin 110 cytotoxic agent (CT) 11 cytotoxic chemotherapy 61 cytotoxic T lymphocytes (CTLs) 234 cytotoxic T-lymphocytes (CTL) 13 D dactinomycin 148 daunorubicin 2, 101, 132, 137, 148, 170, 217, 231 daunorubicin (Dnr) 142 decitabine 11, 66, 134, 241 del 9p21 182 del(6q) 99 dendritic cells (DCs) 234 deoxyguanosine 278 deoxyguanosine triphosphate (dGTP) 143, 243 dexamethasone 68, 132, 211, 239, 267–268 dexamethasone (DEXA) 170 diabetes insipidus 265 disseminated intravascular coagulation (DIC) 284 donor lymphocyte infusion (DLI) 62, 220 Down syndrome 25, 51, 83 Down syndrome (DS) 40 doxorubicin 101, 276 Drosophila runt protein 34 E E. coli asparaginase 141 E2A gene 125 edelfosine 233 Effect of Colony Stimulating Factors (CSFs) 6 enhancer binding protein (CREB) 36 enzyme-linked immunoassay (ELISA) 141 EORTC study 11 eosinophilia 110, 122 epipodophyllotoxin inhibitors 36 epipodophyllotoxins 53 episomes 99 Epstein-Barr virus (EBV) 84 estrogen receptor 99 ETO gene 35 etoposide 61, 233, 270 ETV-6 gene 126 ETV6 98 eukemia free survival (LFS) 231 European Prognostic Index (EPI) 58 ex vivo purging 233 expression microarrays 127 extramedullary disease (EMD) 70 F Factor V Leiden 285 Fanconi anemia 83 Fanconi’s anemia 48 fibrinogen 285 fibronectin 265 filgrastim 138 FISH, see fluorescent in situ hybridization 32–33 flow cytometry 29, 31, 114, 249–250, 249 FLT3 23, 37 FLT3 inhibitors 66 FLT3 mutation 71 fludarabine 239, 278 fluorescent in situ hybridization (FISH) 32 forodesine hydrochloride 212 FRALLE-93 protocol 154 fusion protein 178 G GATA1 is zinc finger transcription factor 37 GATA1 mutations 39 gemtuzumab ozogamicin 69 gemtuzumab ozogamicin (GO) 61, 64 gemtuzumab ozogamycin 8 gene 96, 98 gene expression profiling 39 German Multicenter Study Group for Adult <strong>Acute</strong> Lymphoblastic Leukemia (GMALL) 167, 207 GET-LALA group 145 GMALL 255 GMALL trials 168 GRAALL trials 154 graft vs. host disease (GVHD) 216 graft-versus-host disease 277 graft-versus-leukemia 277 graft-versus-leukemia (GVL) effect 13 graft-vs.-leukemia (GVL) effect 58, 230 graft-vs.-malignancy (GVM) effect 221 granulocyte colony-stimulating factor (G- CSF) 162 granulocytopenia 138 GVHD 222–223 GVHD, see graft vs. host disease 216, 223, 225 GVL, graft-versus-leukemia 13 GVM, see graft-vs.-malignancy 224 H HAART, see highly active antiretroviral therapy 165 hand mirror ALL 122 hand mirror cell 111 hazardous air pollutants (HAPs) 87 HDAC, see high-dose ara-C 3 hematopoiesis 22 hematopoietic stem cell transplantation 183 – autologous 63 – nonmyeloablative (mini) 63, 62 – matched sibling donor (MSD) 62 – relapse 62, 180 hemoglobin 209 hepatomegaly 110 hepatosplenomegaly 192 high hyperdiploidy 100 high-dose ara-C (HDAC) 3 highly active antiretroviral therapy (HAART) 165 histone acetyltransferases 34 Hodgkin’s disease 53 homeobox gene 126 homeobox genes 40 homeobox genes (HOX) 97 HOX11 oncogene 173
Page 1 and 2:
E.H. Estey · S.H. Faderl · H. M.
Page 3 and 4:
E. H. Estey Department of Leukemia
Page 5 and 6:
VI Table of Contents 14 Philadelphi
Page 7 and 8:
VIII Contributors S. H. Faderl Depa
Page 9 and 10:
X Contributors D. Wartenberg Depart
Page 11 and 12:
Therapy of AML Elihu Estey Contents
Page 13 and 14:
a 1.2 · Standard Therapy 3 Table 1
Page 15 and 16:
a 1.2 · Standard Therapy 5 Table 1
Page 17 and 18:
a 1.2 · Standard Therapy 7 tween G
Page 19 and 20:
a 1.2 · Standard Therapy 9 Fig. 1.
Page 21 and 22:
a 1.2 · Standard Therapy 11 of tre
Page 23 and 24:
a 1.2 · Standard Therapy 13 Table
Page 25 and 26:
a 1.2 · Standard Therapy 15 permit
Page 27 and 28:
a References 17 19. Care RS, Valk P
Page 29 and 30:
a References 19 6-thioguanine in th
Page 31 and 32:
Acute Myeloid Leukemia: Epidemiolog
Page 33 and 34:
a 3.1 · Epidemiology 49 3.1.4 Gend
Page 35 and 36:
a 3.2 · Etiology 51 part of the in
Page 37 and 38:
a 3.2 · Etiology 53 for the develo
Page 39 and 40:
a References 55 38. Crane MM, Stom
Page 41 and 42:
Relapsed and Refractory Acute Myelo
Page 43 and 44:
a 4.2 · Prognostic Factors in Pati
Page 45 and 46:
a 4.3 · Treatment of Relapsed and
Page 47 and 48:
a 4.4 · Hematopoietic Stem Cell Tr
Page 49 and 50:
a 4.6 · Gemtuzumab Ozogamicin 65 T
Page 51 and 52:
a 4.7 · Relapsed and Refractory Ac
Page 53 and 54:
a 4.7 · Relapsed and Refractory Ac
Page 55 and 56:
a References 71 The ability of immu
Page 57 and 58:
a References 73 39. Vogler WR, McCa
Page 59 and 60:
a References 75 95. Sievers EL, Lar
Page 61 and 62:
Part II - Acute Lymphoblastic Leuke
Page 63 and 64:
78 Chapter 5 · Acute Lymphoblastic
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Molecular Biology and Genetics Meir
Page 81 and 82:
a 6.3 · Structural Aberrations 97
Page 83 and 84:
a 6.3 · Structural Aberrations 99
Page 85 and 86:
a 6.5 · Molecular Aberrations 101
Page 87 and 88:
a References 103 clear that homozyg
Page 89 and 90:
a References 105 53. Chim CS, Tam C
Page 91 and 92:
a References 107 122. Lennard L, Li
Page 93 and 94:
Diagnosis of Acute Lymphoblastic Le
Page 95 and 96:
a 8.3 · Cytochemistry and Immunoph
Page 97 and 98:
a 8.5 · Cytogenetic and Molecular
Page 99 and 100:
a 8.5 · Cytogenetic and Molecular
Page 101 and 102:
a References 127 including the reti
Page 103 and 104:
a References 129 47. Kita K, Shirak
Page 105 and 106:
Acute Lymphoblastic Leukemia: Clini
Page 107 and 108:
a 7.3 · Diagnosis 111 or neoplasti
Page 109 and 110:
a 7.3 · Diagnosis 113 Fig. 7.2. Hi
Page 111 and 112:
a 7.3 · Diagnosis 115 The vast maj
Page 113 and 114:
a References 117 dren: Biologic bas
Page 115 and 116:
General Approach to the Therapy of
Page 117 and 118:
a 9.3 · New Agents 133 dose methot
Page 119 and 120:
a References 135 4. Gökbuget N, Ho
Page 121 and 122:
138 Chapter 10 · Recent Clinical T
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
146 Chapter 11 · Conventional Ther
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
ALL Therapy: Review of the MD Ander
Page 145 and 146:
a 12.2 · The Hyper-CVAD Regimen in
Page 147 and 148:
a 12.3 · Subset-Specific Approache
Page 149 and 150:
Treatment of Adult ALL According to
Page 151 and 152:
a 13.2 · Therapy for Younger (15-6
Page 153 and 154:
a 13.3 · Therapy of Ph/BCR-ABL-Pos
Page 155 and 156:
a 13.5 · Prognostic Factors 173 13
Page 157 and 158:
a References 175 Only patients with
Page 159 and 160:
Philadelphia Chromosome-Positive Ac
Page 161 and 162:
a 14.2 · Molecular Biology of the
Page 163 and 164:
a 14.3 · Treatment of Ph+ ALL 181
Page 165 and 166:
a 14.4 · Hematopoietic Stem Cell T
Page 167 and 168:
a References 185 2. Kurzrock R, Sht
Page 169 and 170:
a References 187 56. Mori T, Manabe
Page 171 and 172:
a References 189 acute lymphoblasti
Page 173 and 174:
192 Chapter 15 · Burkitt’s Acute
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
204 Chapter 16 · Treatment of Lymp
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
216 Chapter 17 · The Role of Allog
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
230 Chapter 18 · The Role of Autol
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220: 238 Chapter 19 · Novel Therapies i
Page 229 and 230: 248 Chapter 20 · Minimal Residual
Page 245 and 246: 264 Chapter 21 · Central Nervous S
Page 257 and 258: 276 Chapter 22 · Relapsed Acute Ly
Page 259 and 260: 278 Chapter 22 · Relapsed Acute Ly
Page 261 and 262: Emergencies in Acute Lymphoblastic
Page 263 and 264: a 23.5 · Hyperleukocytosis 283 LA
Page 265 and 266: a 23.9 · Neurological Complication
Page 267 and 268: a References 287 29. Hingorani AD,
Page 269: Subject Index A aberrant methylatio
Page 273 and 274: a Subject Index 293 MUD, see matche
show all

Acute Leukemias - Republican Scientific Medical Library

Create successful ePaper yourself

Delete template?

Save as template?